Australia's Invex Therapeutics climbs on neuro drug trial nod in France

Invex Therapeutics

21/04/2023 04:03

** Shares of Invex Therapeutics  IXC.AX  jump as much as
6.7% to A$0.475
    ** Co says it has received approval to begin IIH EVOLVE
Phase III clinical trial in France
    ** Says trial is designed to meet approval requirements of
Presendin for treatment of Idiopathic Intracranial Hypertension
in the EU, UK and Australia
    ** Shares post their biggest intraday pct gain since April 3
    ** Stock has risen 6.7% so far this week, on track for best
week since Dec. 2, 2022 if gains hold

 (Reporting by Echha Jain in Bengaluru)
 ((Echha.jain@thomsonreuters.com))